

Hossein Pakdaman, M.D

Professor of Neurology Beheshti University School of Medicine since 1990.

Professional Society Memberships:

Director of Medical Education in Loghman Hakim Medical Center (1979-1982)
Associate of the Education Deputy of Beheshti University School of Medicine (1980-1982)
Head of Neurology Service in Loghman Hakim Medical Center (since 1978)
Chairman of Neurology Department Beheshti University School of Medicine (since 1978)
Director of Iranian Neurological Board Examination (since 1978)
President of Iranian Neurological Congress (since 1974)
President of 16 International Iranian Neurological Association (since 1991)
Chairman of Iranian Neurological Journal (since 1998).

Journal Article (English)

۱. **A Novel Pathogenic Tau Conformer Playing Part in Tau Pathology in Human Neurons Upon Aging Stress**
N Tofigh, S Agahi, G Riazi, H Pakdaman, MG Moazzam
۲. **A Long-term Study of NeuroAid (MLC601, MLC901) in Patients with Alzheimer's Disease; An Extension 8-year Follow-up Study**
H Pakdaman, A Amini Harandi, K Gharagozli, F Siavoshi, ...
Current Aging Science 16 (3), 234-239
۳. **Multiple sclerosis infected by human lymphotropic virus type-1-associated myelopathy/tropical spastic paraparesis T-cell; a case report**
S Shahbeigi, M Bolourchian, A Altintas, K Gharegozli, H Pakdaman
Journal of the Neurological Sciences 455
۴. **A randomized open-label clinical trial on the effect of Amantadine on post Covid 19 fatigue**
AA Harandi, H Pakdaman, A Medghalchi, N Kimia, A Kazemian, ...
Scientific Reports 14 (1), 1343
۵. **Retraction Note: The Interplay of Tau Protein and β -Amyloid: While Tauopathy Spreads More Profoundly Than Amyloidopathy, Both Processes Are Almost Equally Pathogenic**
M Pourhamzeh, MT Joghataei, S Mehrabi, R Ahadi, SMM Hojjati, N Fazli, ...
Cellular and molecular neurobiology 44 (1), 29
۶. **Risk of depression after Parkinson's disease, stroke, multiple sclerosis, and migraine in an Iranian population and assess psychometric characteristics of three prevalent ...**
M Salari, H Pakdaman, M Etemadifar, F HojjatiPour, M Khalkhali, ...
IBRO Neuroscience Reports 16, 241-248
۷. **Alterations of White Matter Structure in Patients with Fibromyalgia: A Systematic Review of Diffusion Tensor Imaging Studies**
S Lotfinia, A Afshar, M Roozbeh, H Pakdaman, M Roozbeh
۸. **The Interplay of Tau Protein and beta-Amyloid: While Tauopathy Spreads More Profoundly Than Amyloidopathy, Both Processes Are Almost Equally Pathogenic (Retraction of Vol 41 ...**
M Pourhamzeh, MT Joghataei, S Mehrabi, R Ahadi, SMM Hojjati, N Fazli, ...
CELLULAR AND MOLECULAR NEUROBIOLOGY 44 (1)
۹. **Cerebral hemodynamic response to generalized anxiety disorder** AA Harandi, N Kimia, A Medghalchi, E Sharifipour, H Pakdaman, Psychiatry Research: Neuroimaging 333, 111654
۱۰. **MLC901 in hypoxic-ischemic brain injury patients: A double-blind, randomized placebo-controlled pilot study**, H Pakdaman, K Gharagozli, F Karamiani, MS Goushki, S Moini, .Medicine ۱۰۲ (۲۳)
۱۱. **The effect of atorvastatin on the blood-brain barrier biomarkers in acute intracerebral hemorrhage, a pilot clinical trial**, L Simani, M Ramezani, N Ahmadi, F Abazari, S Raminpard, M Shojaei, .Brain Hemorrhages 4 (2), 53-56

۱۲. **Recovery of Acute Ophthalmoplegia after Hyaluronic Acid Filler Injections to the Temples: A Case Report and Review of the Literature** .F Tabatabaei, A Azimi, SS Tabatabaei, H Pakdaman . Archives of Plastic Surgery 50 (02), 148-152
۱۳. **A long-term study of NeuroAid (MLC601, MLC901) in Patients with Alzheimer's disease; An Extension 8-year Follow-up Study.**H Pakdaman, K Gharagozli, F Siavoshi, E Sharifipour, A Esfandani, Current Aging Science
۱۴. **Vascular endothelial growth factor as a predictive and prognostic biomarker for multiple sclerosis** .A Amini Harandi, F Siavoshi, S Shirzadeh Barough, A Amini Harandi, Neuroimmunomodulation 29 (4), 476-48
۱۵. **Fampridine in multiple sclerosis patients with acute phase of cervical transverse myelitis: a double-blind, randomized placebo-controlled trial.**H Pakdaman, F Karamiani, F Mohammadi, F Siavoshi, S Ilkhani, Neurological Sciences: Official Journal of the Italian Neurological Society ...
۱۶. **Developing a novel prediction model in opioid overdose using machine learning; a pilot analytical study.**E Sakhaee, A Amirahmadi, M Mahdiani, M Shojaei, .Health science reports 5 (5), e767
۱۷. **The outbreak of methanol intoxication during COVID-19 pandemic: prevalence of brain lesions and its predisposing factors** .L Simani, M Ramezani, M Roozbeh, S Shadnia, H Pakdaman .Drug and chemical toxicology 45 (4), 1500-1503
۱۸. **P38 initiates degeneration of midbrain GABAergic and glutamatergic neurons in diabetes models** A Farhadi, M Totonchi, SM Nabavi, H Baharvand, H Pakdaman, .European Journal of Neuroscience ۵۶ (۱), ۳۷۵۵-۳۷۷۸
۱۹. **Association of changed serum brain biomarkers with perihematomal edema and early clinical outcome in primary ICH patients** L Simani, M Ramezani, E Mohammadi, F Abbaszadeh, E Karimialavijeh, .The Neurologist 27 (4), ۱۶۸-۱۷۲
۲۰. **Tau nuclear translocation is a leading step in tau pathology process through P53 stabilization and nucleolar dispersion** .S Roqanian, S Ahmadian, SM Nabavi, H Pakdaman, M Shafieezadeh, .Journal of Neuroscience Research 100 (4), 1084-1104
۲۱. **Is Selenium Supplementation Beneficial in Acute Ischemic Stroke?** M Ramezani, L Simani, S Abedi, H Pakdaman .The Neurologist 27 (2), 51-55
۲۲. **Repetative Transcranial Magnetic Stimulator (rTMS) Characterization and How to Develop the Functionalities for Treating Neural Disorders** .A Pirayeshfar, H Pakdaman, MB Ghofrani, M Roozbeh, K Gharagozli Journal of Otorhinolaryngology and Facial Plastic Surgery 8 (1), 1-11
۲۳. **Factors predisposing patients with temporal lobe epilepsy to seizure cluster** .M Asadollahi, F Maghsudloo, L Simani, H Pakdaman .Current Journal of Neurology 21 (1), 12
۲۴. **Migraine headache as a presenting feature of multiple sclerosis: a case report.**MM Rabiei, Z Cheraghi, M Ramezani, H Pakdaman .International Clinical Neuroscience Journal 8 (4), 208-211
۲۵. **Comprehensive review on neuro-COVID-19 pathophysiology and clinical consequences** H Jafari Khaljiri, M Jamalkhah, A Amini Harandi, H Pakdaman, M Moradi, .Neurotoxicity research 39 (5), 1613-1629

۲۶. **The interplay of tau protein and β -amyloid: while tauopathy spreads more profoundly than amyloidopathy, both processes are almost equally pathogenic** .M Pourhamzeh, MT Joghataei, S Mehrabi, R Ahadi, SMM Hojjati, N Fazli, .Cellular and molecular neurobiology 41, 1339-1354
۲۷. **Epilepsy lifetime prevalence in Iran: a large population-based national survey** .H Pakdaman, AA Harandi, K Gharagozli, F Alaeddini, A Esfandani, .Scientific Reports 11 (1), 9437
۲۸. **Prevalence and correlates of chronic fatigue syndrome and post-traumatic stress disorder after the outbreak of the COVID-19** .L Simani, M Ramezani, IA Darazam, M Sagharichi, MA Aalipour, .Journal of neurovirology 27, 154-159
۲۹. **Lifestyle assessment in young adults with ischemic stroke: One cross-sectional study in Iran**
A Chouhdari, HS Farahani, H Pakdaman, K Heidari, K Ebrahimzadeh .International Journal of Preventive Medicine
۳۰. **Does vitamin D administration play a role in outcome of patients with acute ischemic stroke? A randomized controlled trial** .O Rezaei, M Ramezani, M Roozbeh, B Fazeli, M Hajjesmaeili, .Current Journal of Neurology 20 (1), 8
۳۱. **Neurocognitive manifestations of SARS-CoV2: a narrative review of mechanisms** .M Roozbeh, M Roozbeh, H Pakdaman, SA Sobhanian, A Edalatkhah, .International Clinical Neuroscience Journal 8 (1), 3-9
۳۲. **MLC901 for moderate to severe traumatic brain injury: pilot, randomized, double-masked, placebo-controlled trial** .H Pakdaman, AA Harandi, A Esfandani, A Yousefi, MK Pol, B Mansouri, .Open Access Journal of Complementary & Alternative Medicine 2, 257-62
۳۳. **P38 Initiates Diabetic Neurodegeneration Through Glutamatergic and GABAergic Neurons** .A Farhadi, M Totonchi, SM Nabavi, H Baharvand, H Pakdaman
۳۴. **The role of anxiety and cortisol in outcomes of patients with Covid-19** .M Ramezani, L Simani, E Karimialavijeh, O Rezaei, M Hajjesmaeili, Basic and clinical neuroscience 11 (2), 179
۳۵. **Attention and inhibitory control deficits in patients with genetic generalized epilepsy and psychogenic nonepileptic seizure** .L Simani, M Roozbeh, M Rostami, H Pakdaman, M Ramezani, Epilepsy & Behavior 102, 106672
۳۶. **Mortality prediction in patients with post-operative meningitis: one longitudinal study in Iran** .A Chouhdari, M Hajjesmaeili, O Rezaee, M Samadian, G Sharifi, .Archives of Neuroscience 6 (2)
۳۷. **Stem cell therapy in Alzheimer's disease: possible benefits and limiting drawbacks** .M Alipour, SM Nabavi, L Arab, M Vosough, H Pakdaman, E Ehsani, .Molecular biology reports 46, 1425-1446
۳۸. **cis pT231-Tau Drives Neurodegeneration in Bipolar Disorder** .R Naserkhaki, S Zamanzadeh, H Baharvand, SM Nabavi, H Pakdaman, ACS Chemical Neuroscience 10 (3), 1214-12
۳۹. **Multiple Sclerosis Infected by Human Lymphotropic Virus Type-1 (HTLV-1)-Associated Myelopathy/Tropical Spastic Paraparesis T-Cell (HAM/TSP); A Case Report** .S Shahbeigi, M Bolouchian, A Altintas, K Gharegozli, H Pakdaman. Open Access Journal of Neurology & Neurosurgery 10 (1), 8-11

۴۰. **Lifestyle assessment in two age groups of ischemic stroke: A cross-sectional study in Iran** .A Chouhdari, H Shahrabi, H Pakdaman, K Heidari, K Gharagozli .Social Determinants of Health 5 (3), ۲۰۰-۲۰۶
۴۱. **The Relationship between Platelet Volume Indices (PVIs) and Epileptic Seizure**.O Rezaei, S Niknazar, M Amirdosara, S Purnajaf, H Pakdaman, Journal of Otorhinolaryngology and Facial Plastic Surgery 5 (1), 1-5
۴۲. **A randomized double-blind trial of comparative efficacy and safety of Avonex and CinnoVex for treatment of relapsing-remitting multiple sclerosis** .H Pakdaman, M Abbasi, K Gharagozli, F Ashrafi, H Delavar Kasmaei, Neurological Sciences 39, 2107-2113
۴۳. **Balo's concentric sclerosis: an update and comprehensive literature review** .A Amini Harandi, A Esfandani, H Pakdaman, M Abbasi, MA Sahraian .Reviews in the Neurosciences 29 (8), 873-882
۴۴. **O2: Epilepsy Lifetime Prevalence in Iran: A Population-Based National Study Survey** .H Pakdaman .The Neuroscience Journal of Shefaye Khatam 6 (3), 2-2
۴۵. **Efficacy and safety of MLC601 in patients with mild to moderate Alzheimer disease: an extension 4-year follow-up study** .H Pakdaman, K Gharagozli, M Abbasi, A Sobhanian, A Bakhshandehpour, Dementia and Geriatric Cognitive Disorders Extra 8 (1), 174-179
۴۶. **A Review on Stem Cell Therapy in Cerebral Palsy with a Focus on Motor Function Improvement** .AR Zali, AA Harandi, S Oraee-Yazdani, F Ashrafi, H Pakdaman, .Brieflands
۴۷. **A Review on Stem Cell Therapy in Cerebral Palsy with a Focus on Motor Function Improvement** F Ashrafi, AR Zali, H Pakdaman, B Behnam, MA Ahmadi, AA Harandi, .Archives of Neuroscience 5 (1)
۴۸. **MLC601 in vascular dementia: an efficacy and safety pilot study** .H Pakdaman, A Amini Harandi, K Gharagozli, M Abbasi, M Ghaffarpour, .Neuropsychiatric Disease and Treatment, 2551-2557
۴۹. **Health-related quality of life in patients with relapsing-remitting multiple sclerosis treated with subcutaneous interferon β -1a in Iran** .H Pakdaman, A Amini Harandi, K Gharagozli, M Abbasi, A Tabassi, International Journal of Neuroscience 127 (6), 501-507
۵۰. **Efficacy and safety of MLC601 in the treatment of mild cognitive impairment: a pilot, randomized, double-blind, placebo-controlled study** .H Pakdaman, A Amini Harandi, M Abbasi, H Delavar Kasmaei, F Ashrafi, Dementia and Geriatric Cognitive Disorders Extra 7 (1), 136-142
۵۱. **S100 B: A new concept in neurocritical care** .O Rezaei, H Pakdaman, K Gharehgozli, L Simani, A Vahedian-Azimi, Iranian Journal of Neurology 16 (2), 83
۵۲. **Head trauma as a precipitating factor for late-onset Leigh syndrome: a case report** .F Ashrafi, H Pakdaman, M Arabahmadi, B Behnam .Emergency 5 (1)
۵۳. **Vagus nerve stimulation in drug-resistant epilepsy: the efficacy and adverse effects in a 5-year follow-up study in Iran** .H Pakdaman, A Amini Harandi, M Abbasi, M Karimi, MA Arami, SA Mosavi, Neurological Sciences 37, 1773-1778
۵۴. **Correlation of MRI findings and cognitive function in multiple sclerosis patients using montreal cognitive assessment test** .F Ashrafi, B Behnam, MA Ahmadi, MS Taheri, HR Haghghatkhah, Medical Journal of the Islamic Republic of Iran 30, 357

۵۵. **Persian version of frontal assessment battery: Correlations with formal measures of executive functioning and providing normative data for Persian population** .S Asaadi, F Ashrafi, M Omidbeigi, Z Nasiri, H Pakdaman, A Amini-Harandi *Iranian journal of neurology* 15 (1), 16
۵۶. **Effects of Arachidonyl-2'-chloroethylamide (ACEA) as a CB1 receptor agonist in the rat model of Parkinson's disease** .M Omidbeigi, S Asaadi, Z Gholizadeh, H Pakdaman .*Parkinsonism & Related Disorders* 22, e147
۵۷. **Association between Cognitive function and metabolic syndrome using Montreal Cognitive Assessment Test.**F Ashrafi, B Behnam, M Arab Ahmadi, H Pakdaman, S Mohamad Ali.*International Clinical Neuroscience Journal* 2 (3), 91-9
۵۸. **Effects of high-frequency repetitive transcranial magnetic stimulation on motor functions in patients with subcortical stroke** .F Ashrafi, A Rokni, S Asaadi, H Pakdaman, F Yourdkhani .*Caspian Journal of Neurological Sciences* 1 (1), 1-6
۵۹. **Effectiveness and safety of MLC601 in the treatment of mild to moderate Alzheimer's disease: a multicenter, randomized controlled trial** H Pakdaman, AA Harandi, H Hatamian, M Tabatabae, *Dementia and geriatric cognitive disorders extra* 5 (1), 96-106
۶۰. **NeuroAiDTM (MLC601, MLC901): A New Bench-to-Bedside Approach to the Treatment of Ischemic Brain Injury**, M Dib, I Zahra, S Chankrachang, A Czlonkowska, A Fedin, H Manvelyan,, *European Journal of Medicinal Plants* 5 (2), 117-126
۶۱. **Characteristics of multiple sclerosis in the Middle East with special reference to the applicability of international guidelines to the region**, AM Al Tahan, I Alsharoqi, SA Bohlega, M Dahdaleh, A Daif, D Deleu,,*International Journal of Neuroscience* 124 (9), 635-641
۶۲. **Frontal assessment battery in a Persian population with Parkinson's disease**, F Ashrafi, M Daemi, S Asaadi, D Ommi, Z Nasiri, H Pakdaman, *International Clinical Neuroscience Journal* 1 (1), 18-21
۶۳. **Effectiveness and Safety of MLC601 in the Treatment of Mild to Moderate Alzheimer's disease: A Multicenter, Randomized Controlled Trial.** *Dement Geriatr Cogn Dis Extra.* 2015 Mar 7;5(1):96-۱۰۶. [DOI: 10.1007/s11357-015-0457-6](#).
۶۴. **Trigeminal neuralgia as the first clinical manifestation of anti-hu paraneoplastic syndrome induced by a borderline ovarian mucinous tumor.** *Case Rep Neurol.* 2014 Jan 22;6(1):7-13.
۶۵. **Pharmacokinetic and pharmacodynamic properties of the new AEDs: A review article.** *Iran J Neurol.* ۲۰۱۳;۱۲(۴):۱۵۷-۶۵.
۶۶. **Characteristics of multiple sclerosis in the Middle East with special reference to the applicability of international guidelines to the region.** *Int J Neurosci.* 2014 Sep;124(9):635-41.
۶۷. **Efficacy and Tolerability of MLC601 in Patients with Mild to Moderate Alzheimer Disease who were Unable to Tolerate or Failed to Benefit from Treatment with Rivastigmine.** *British Journal of Medicine & Medical Research.* 2013; 3(2): 341-350.
۶۸. **Vitamin D3 concentration correlates with the severity of multiple sclerosis.** *Int J Prev Med.* 2013 May;4(5):585-91.
۶۹. **Epidemiology of headaches in Tehran urban area: a population-based cross-sectional study in district 8, year 2010.** *Neurol Sci.* 2012 Sep 26.
۷۰. **Frequency distribution of the first clinical symptoms in the Iranian population with multiple sclerosis.** *Iranian J Neurology.* 2012; 11(3): 118-120.

۷۱. **Is it time to revise the classification of geographical distribution of MS?** Ir J Neurol. 2012; 11(2).
۷۲. **Barking seizure: acute episodes of barking in a 75-year-old previously healthy man.** Seizure. 2012 May;21(4):304-6.
۷۳. **Serum prolactin level in patients with relapsing-remitting multiple sclerosis during relapse.** J Clin Neurosci. 2012 Apr;19(4):622-3.
۷۴. **Old findings in multiple sclerosis but a new application.** Clin Neurol Neurosurg. 2012 May;114(4):411.
۷۵. **The effect of NeuroAiD™ (MLC601) on cerebral blood flow velocity in subjects' post brain infarct in the middle cerebral artery territory.** Eur J Intern Med. 2011 Oct;22(5):509-13.
۷۶. **Safety and Efficacy of MLC601 in Iranian Patients after Stroke: A Double-Blind, Placebo-Controlled Clinical Trial.** Stroke Res Treat. 2011;2011:721613.
۷۷. **Multiple sclerosis in Iran: a demographic study of 8,000 patients and changes over time.** Eur Neurol. 2010;64(6):331-6.
۷۸. **Influence of CYP2C9 polymorphism on metabolism of valproate and its hepatotoxin metabolite in Iranian patients.** Toxicol Mech Methods. 2010 Oct;20(8):452-7. Biosimilars: opinion of an expert panel in the Middle East. Curr Med Res Opin. 2008 Oct;24(10):2897-903.
۷۹. **International Working Group for Treatment Optimization in MS. Integrating an evidence-based assessment of benefit and risk in disease-modifying treatment of multiple sclerosis.** Curr Med Res Opin. 2007 Nov;23(11):2823-32.
۸۰. **Effect of early interferon beta-1a therapy on conversion to multiple sclerosis in Iranian patients with a first demyelinating event.** Acta Neurol Scand. 2007 Jun;115(6):429-31.
۸۱. Pakdaman H, Fallah A, Sahraian MA, Pakdaman R, Rahimian E. **Early-onset multiple sclerosis: a report of a monozygotic twin pair with different treatment strategies and outcomes.** Eur J Neurol. 2007 Feb;14(2):e10.
۸۲. **Treatment of early onset multiple sclerosis with suboptimal dose of interferon beta-1a.** europediatrics.2006 Aug;37(4):257-60.
۸۳. **Quality of life of people with epilepsy in Iran, the Gulf, and Near East.** Epilepsia. 2005 Jan;46(1):132-40.
۸۴. **A six month cross-section study on prevalence and characteristics of pain in 100 Iranian patients with Multiple Sclerosis,** Multiple Sclerosis Journal , Volume 10, Supplement 2, September 2004, p229.
۸۵. **Childhood onset of inflammatory demyelinating diseases of the central nervous system: a retrospective review.** Multiple Sclerosis Journal, Volume 10, Supplement 2, September 2004, p342.
۸۶. **Assessing the treatment of relapsing-remitting multiple sclerosis beta -1a in 2 groups of Iranian patients (120) with mild to moderate disability after one year ,** Multiple Sclerosis Journal , Volume 10, Supplement 2, September 2004 , p573.
۸۷. **Direct comparison study of the effect of beta-interferons in Iranian patients with Multiple Sclerosis. (Results of a 6-year therapy),** Journal of Neurology (ENS), Volume 251, suppl.3, June 2004, p230.
۸۸. **Lamictal as an add on therapy in the treatment of 100 Iranian patients with Trigeminal Neuralgia ,** Journal of Neurology (ENS) , Volume 251, suppl.3 ,June 2004, p550.

٨٩. **The epidemiology of Multiple Sclerosis in Iran** , Journal of Neurology (ENS) , Volume 250, suppl.2, May 2003, p774.
٩٠. **Comparison Effectiveness and safety of Sodium Valproate, Carbamazepine and Topamax in 180 Iranian with psychomotor epilepsy**, 1st Sharm el Sheikh International Epilepsy conference, March 5-8, 2003, p42.
٩١. **Assessment of signs and symptoms in Multiple Sclerosis and evaluation of disability condition in patients referred to MS research clinics from1997-2001 (2412 cases)** , Multiple Sclerosis Journal , Volume8, Supplement 1, September 2002 , p41.
٩٢. **The effect of Interferon Beta on the cognitive dysfunction of 100 Iranian patients with Multiple Sclerosis**, Multiple Sclerosis Journal, Volume8, Supplement 1, September 2002, p288.
٩٣. **The changes in the transmission functioning of the ulnar nerve in a high power magnetic field.** Electromyogr Clin Neurophysiol. 2001 Jul-Aug;41(5):269-71.
٩٤. **Comparison of the efficacy and tolerability of treatment Carbamazepin and Sodium Valproate monotherapy for newly diagnosed complex partial seizure.** Iranian Journal of Neurology, Volume 1, Number 4,winter 2001.
٩٥. **Effectiveness, tolerability and safety of Topiramate in treatment of children with resistant epilepsy.** - Iranian Journal of Neurology, Volume 2, Summer 2001
٩٦. **Double blind placebo controlled randomized parallel group trials study compared the efficacy, safety and tolerability of oral Sumatriptan on 40 Iranian patients with acute migraine headaches.** – Iranian Journal of Neurology, Volume 1, Number 1,May 2001
٩٧. **Comparison of the efficacy and tolerability of Avonex, Rebif and betaferon on 100 Iranian MS patients (5 years studies) cognitive dysfunction in multiple sclerosis.** - Iranian Journal of Neurology, Volume 1, Number 1,May 2001
٩٨. **Assessment of sign and symptom in Iranian Multiple Sclerosis Patient:** Iranian Neurological Journal Volume 2, 2001).
٩٩. **The effect of interferon beta on cognitive dysfunction of 100 Iranian patients with multiple sclerosis-** MS Journal, Volume2, 1999.
١٠٠. **Open label clinical study on effectiveness of Topiramate as add -on therapy on 22 patients with partial onset of seizure with or without generalization;** Epilepsia (volum16, 1999)
١٠١. **Efficacy and Safety of Lamotrigine as add-on Therapy on 13,132 children and adult Iranian patient with treatment resistant Epilepsy:** Epilepsia (volume 14,1999).
١٠٢. **Vagus Nerve Stimulation:** Epilepsia (volume 1999).

Books:

- 1-Clinical Neurology
- 2-Epilepsy
- 3-Intercranial Doppler Sonography.